iShares Core Growth Allocation ETF vs Boston Scientific Corporation — how do they compare? iShares Core Growth Allocation ETF trades at $69.87, while Boston Scientific Corporation trades at $51 (market cap $71.46B). The key difference: iShares Core Growth Allocation ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| AOR | BSX | |
|---|---|---|
52-Week High | $70.12 | $108.14 |
52-Week Low | $62.26 | $42.63 |
Market Cap | — | $71.46B |
Sector | — | Health |
Enterprise Value | — | $83.55B |
Signals from Pluang's Aura AI — not financial advice
AOR, the iShares Core Growth Allocation ETF, trades at $70.12, up 0.57% on the day, with a bullish technical signal driven by moving averages. The ETF maintains a fixed 60/40 stock/bond allocation, rebalances semiannually, and offers low-cost exposure with a 0.20% fee. Recent news highlights its role as a core holding but notes long-term underperformance versus the S&P 500 over the past decade.
The outlook for AOR hinges on its diversified asset allocation strategy providing stability, though it faces risks from equity and fixed income market volatility. Its simplicity appeals to investors seeking a hands-off approach, but competition from pure equity funds and interest rate sensitivity are key considerations for potential returns.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →